Skip to main content
. 2017 Sep 18;28(12):3000–3008. doi: 10.1093/annonc/mdx527

Table 3.

Response assessment and efficacy summary, according to investigator assessment

MET status
MET + (=26) MET − (=2) Total (=28)
N (%) N (%) N (%)
Best response
 Complete response
 Partial response 1 0 1
 Stable disease 17 (65.4) 1 18 (64.3)
 Progressive disease 8 (30.8) 1 9 (32.1)
 Objective response rate 3.8% 0% 3.6%
 (95% CI ) (0.1% to 19.6%) (0.1% to 18.3%)
 Disease control rate 69.2% 50% 67.9%
 (95% CI) (48.2% to 85.7%) (1.3% to 98.7%) (47.7% to 84.1%)
Progression-free survival
 Alive with no evidence of disease 2 0 2
 Progression of CCSA or died 24 (92.3) 2 26 (92.9)
 Median in days 131 96.5 128.5
 (95% CI) (49–235) (66–127) (66–168)
 1-Year progression-free survival rate 7.7% 0 7.1%
 (95% CI) (1.3% to 21.7%) (1.3% to 20.4%)
 2-Year progression-free survival rate 7.7% n.a. 7.1%
 (95% CI) (1.3% to 21.7%) (1.3% to 20.4%)
Survival status
 Alive 4 (15.4) 1 5 (17.9)
 Dead 22 (84.6) 1 23 (82.1)
 Reason of death :
  Progression of CCSA 18 (69.2) 1 19 (67.9)
  Toxicity and progression of CCSA 1 0 1
  Other reason 1 0 1
  Unknown 2 0 2
 Median in days 277 n.a. 286
 (95% CI) (232–442) (232–442)
 1-Year survival rate 36.1% 100% 40.8%
 (95% CI) (18.2% to 54.3%) (100% to 100%) (22.6% to 58.3%)
 2-Year survival rate 9.4% 50.0% 10.6%
 (95% CI) (1.7% to 25.3%) (0.6% to 91.0%) (2.1% to 27.4%)

CI, confidence interval.